Dr. Scott L. Friedman Joins MAX BioPharma’s Scientific Advisory Board to Advance MASH Program

It is with great honor and pleasure that we report that Dr. Scott L. Friedman has joined MAX BioPharma's Scientific Advisory Board. Dr. Friedman is Dean for Collaborative Research & Partnerships, Director of the Institute for Liver Research, and Chief Emeritus of Liver Diseases at the Icahn School of Medicine at Mount Sinai School of Medicine in New York City. He has had a stellar career as a physician and scientist, and his seminal discoveries around liver disease, metabolic dysfunction-associated steatohepatitis (MASH), and fibrosis, continue to shape how research and therapeutic development in these indications progress. We have benefited from Dr. Friedman's insights, guidance, and collaborative pursuit in developing our lead therapeutic candidate, Oxy210, for targeting MASH, and we look forward to continuing to rely on him as a key resource as we advance our MASH program